DK200001151A - Ny krystallinsk form af 6-hydorxy-3-(-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]tihiophen hydrochlorid - Google Patents

Ny krystallinsk form af 6-hydorxy-3-(-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]tihiophen hydrochlorid Download PDF

Info

Publication number
DK200001151A
DK200001151A DK200001151A DKPA200001151A DK200001151A DK 200001151 A DK200001151 A DK 200001151A DK 200001151 A DK200001151 A DK 200001151A DK PA200001151 A DKPA200001151 A DK PA200001151A DK 200001151 A DK200001151 A DK 200001151A
Authority
DK
Denmark
Prior art keywords
piperidin
benzo
phenoxy
ethoxy
hydroxy
Prior art date
Application number
DK200001151A
Other languages
English (en)
Inventor
Julie Kay Bush
Preston Charles Conrad
Merlyn Gerard Flom
Wayne Douglas Luke
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK200001151A publication Critical patent/DK200001151A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

Patentkrav : 1. Krystallinsk 6-hydroxy-3-(4-[2-(piperidin-l-yl)-ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen hy-drochlorid hydrat (F-I), der har et røntgenstrålediffraktionsmønster, som omfatter de følgende toppe: 7,9 +_0,2, 10,7 +0,2, 14,9 +0,2, 15,9 +0,2, 18,3 +0,2 og 20,6 +0,2° i 2Θ, når det er opnået fra en kobberbestrålingskilde. 2. Lægemiddelformulering omfattende den krystallinske forbindelse ifølge krav 1, en eller flere lægemiddelbærere, fortyndingsmidler eller excipiens, og eventuelt østrogen, eventuelt progestin, eventuelt en aromatasein-hibitor, eventuelt en LHRH-analog og eventuelt en acetyl-cholinesterase(AChE)inhibitor. 3. Formulering ifølge krav 2, som omfatter den krystallinske forbindelse ifølge krav 1, en eller flere lægemiddelbærere, fortyndingsmidler eller excipiens, og østrogen . 4. Formulering ifølge krav 3, hvori østrogenet er Prema-rin®. 5. Formulering ifølge krav 2, som omfatter den krystallinske forbindelse ifølge krav 1, en eller flere lægemiddelbærere, fortyndingsmidler eller excipiens og progestin . 6. Formulering ifølge krav 5, hvori progestinet er valgt blandt gruppen bestående af norethylnodrel og norethin-dron. 7. Formulering ifølge krav 2, som omfatter den krystallinske forbindelse ifølge krav 1, en eller flere lægemiddelbærere, fortyndingsmidler eller excipiens og en AChE-inhibitor. 8. Formulering ifølge krav 7, hvori AChE-inhibitoren er valgt blandt gruppen bestående af physostigminsalicylat, tacrin hydrochlorid og donepezil hydrochlorid. 9. Formulering ifølge krav 2, som omfatter den krystallinske forbindelse ifølge krav 1, en eller flere lægemiddelbærere, fortyndingsmidler eller excipiens, østrogen og progestin. 10. Forbindelsen ifølge krav 1 til undertrykkelse af patologiske tilstande valgt blandt gruppen bestående af livmoderfibrosis, endometriosis, aortal glatmuskelcelle-formering, restenosis, brystcancer, livmodercancer, pro-statacancer, godartet prostata-hyperplasia, bentab, osteoporosis, hjerte/karsygdomme, hyperlipidomia, CNS-forstyrrelser og Alzheimers syge. 11. Forbindelsen ifølge krav 10 til undertrykkelse af brystcancer. 12. Forbindelsen ifølge krav 11, hvori undertrykkelsesmåden er profylaktisk. 13. Forbindelsen ifølge krav 10 til undertrykkelse af ovariecancer. 14. Forbindelsen ifølge krav 10 til undertrykkelse af en-dometrial cancer. 15. Forbindelsen ifølge krav 1 til opregulering af cho-lin-acetyltransferase (ChAT) i pattedyr. 16. Fremgangsmåde til fremstilling af forbindelse ifølge krav 1, som omfatter krystallisering af 6-hydroxy-3-(4-[2-(piperidin-l-yl)ethoxyjphenoxy)-2-(4-methoxy-phenyl)-benzo[b]thiophen hydrochlorid fra tetrahydrofuran.
DK200001151A 1999-07-29 2000-07-28 Ny krystallinsk form af 6-hydorxy-3-(-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]tihiophen hydrochlorid DK200001151A (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14628699P 1999-07-29 1999-07-29
US14757099P 1999-08-06 1999-08-06
US14977399P 1999-08-19 1999-08-19

Publications (1)

Publication Number Publication Date
DK200001151A true DK200001151A (da) 2001-01-30

Family

ID=27386379

Family Applications (1)

Application Number Title Priority Date Filing Date
DK200001151A DK200001151A (da) 1999-07-29 2000-07-28 Ny krystallinsk form af 6-hydorxy-3-(-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]tihiophen hydrochlorid

Country Status (45)

Country Link
EP (1) EP1204656A2 (da)
JP (1) JP2001064277A (da)
KR (1) KR100697177B1 (da)
CN (1) CN1138770C (da)
AR (1) AR031073A1 (da)
AT (1) AT502318A1 (da)
AU (1) AU6335600A (da)
BE (1) BE1013411A3 (da)
BR (1) BR0003209A (da)
CA (1) CA2314682A1 (da)
CO (1) CO5180570A1 (da)
CZ (1) CZ299311B6 (da)
DE (1) DE10036854A1 (da)
DK (1) DK200001151A (da)
DZ (1) DZ3060A1 (da)
FI (1) FI20001722A (da)
FR (1) FR2796944B1 (da)
GB (1) GB2352717A (da)
GR (1) GR1004084B (da)
HK (1) HK1035370A1 (da)
HR (1) HRP20000503B1 (da)
HU (1) HUP0003001A2 (da)
ID (1) ID27078A (da)
IL (1) IL137553A (da)
IT (1) IT1318660B1 (da)
LT (1) LT4790B (da)
LU (1) LU90617B1 (da)
LV (1) LV12623B (da)
MD (1) MD2336G2 (da)
MX (1) MXPA00007461A (da)
MY (1) MY128764A (da)
NL (1) NL1015821C2 (da)
NO (1) NO20003879L (da)
PE (1) PE20010385A1 (da)
PL (1) PL341749A1 (da)
PT (1) PT102502A (da)
RO (1) RO121851B1 (da)
SE (1) SE0002792L (da)
SG (1) SG91296A1 (da)
SI (1) SI20426A (da)
SV (1) SV2002000132A (da)
TR (1) TR200002206A2 (da)
TW (1) TWI276437B (da)
UA (1) UA72885C2 (da)
WO (1) WO2001009116A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE251151T1 (de) * 1999-07-29 2003-10-15 Lilly Co Eli Eine kristalline form von 6-hydroxy-3-(4-(2- (piperidin-1-yl)ethoxy)phenoxy)-2-(4- methoxyphenyl)benzo(b)thiophen-hydrochlorid
US7122203B2 (en) 2000-05-08 2006-10-17 Eli Lilly And Company Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
BR0110620A (pt) * 2000-05-08 2003-04-01 Lilly Co Eli Formulações estabilizadas de 6-hidróxi-3-(4-[2-(piperidin-1-il)etóxi]fenóxi)-2-(4-metoxi fenil)benzo[b]tiofeno e de sais do mesmo
EP1757291A3 (en) * 2000-05-08 2009-07-15 Eli Lilly & Company Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
KR20030037690A (ko) * 2000-10-20 2003-05-14 일라이 릴리 앤드 캄파니 6-히드록시-3-(4-[2-(피페리딘-1-일)에톡시]페녹시)-2-(4-메톡시페닐)벤조[ｂ]티오펜 히드로클로라이드의 신규 결정형
US6921827B2 (en) 2000-11-27 2005-07-26 Eli Lilly And Company Process for preparing 3-aryl-benzo{b} thiophenes
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
PL1773811T3 (pl) * 2004-07-22 2011-02-28 Lilly Co Eli Krystaliczny zmienny hydrat soli hemibursztynianowej (s)-6-(4-(2-((3(9h-karbazol-4-iloksy)-2-hydroksypropylo)amino)-2-metylopropylo)fenoksy)-3-pirydynokarboksy amidu

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE44597A1 (es) * 1995-02-28 1997-10-13 Lilly Co Eli Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
ZA9710262B (en) * 1996-11-19 1999-05-13 Lilly Co Eli Process for the synthesis of benzothiophenes
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.

Also Published As

Publication number Publication date
FI20001722A (fi) 2001-01-30
DE10036854A1 (de) 2001-03-01
AU6335600A (en) 2001-02-19
TWI276437B (en) 2007-03-21
DZ3060A1 (fr) 2004-05-22
NO20003879D0 (no) 2000-07-28
CN1288007A (zh) 2001-03-21
NL1015821C2 (nl) 2002-01-03
LV12623B (en) 2001-07-20
NO20003879L (no) 2001-01-30
SE0002792L (sv) 2001-01-30
HRP20000503B1 (en) 2008-04-30
IT1318660B1 (it) 2003-08-27
ITMI20001759A0 (it) 2000-07-28
PL341749A1 (en) 2001-02-12
HK1035370A1 (en) 2001-11-23
CZ20002716A3 (en) 2001-05-16
CN1138770C (zh) 2004-02-18
AR031073A1 (es) 2003-09-10
IE20000605A1 (en) 2001-04-04
BR0003209A (pt) 2001-03-20
SI20426A (sl) 2001-06-30
GB2352717A (en) 2001-02-07
GB0018641D0 (en) 2000-09-13
RO121851B1 (ro) 2008-06-30
CZ299311B6 (cs) 2008-06-18
FR2796944A1 (fr) 2001-02-02
ID27078A (id) 2001-02-22
UA72885C2 (uk) 2005-05-16
LT2000076A (lt) 2001-02-26
MY128764A (en) 2007-02-28
CA2314682A1 (en) 2001-01-29
HRP20000503A2 (en) 2001-06-30
JP2001064277A (ja) 2001-03-13
KR100697177B1 (ko) 2007-03-21
HUP0003001A2 (hu) 2002-04-29
IL137553A (en) 2005-09-25
IL137553A0 (en) 2001-07-24
PE20010385A1 (es) 2001-04-06
SE0002792D0 (sv) 2000-07-28
MD2336F2 (en) 2003-12-31
WO2001009116A2 (en) 2001-02-08
FR2796944B1 (fr) 2003-01-31
WO2001009116A3 (en) 2001-05-17
GR1004084B (el) 2002-12-11
EP1204656A2 (en) 2002-05-15
BE1013411A3 (fr) 2001-12-04
FI20001722A0 (fi) 2000-07-28
LT4790B (lt) 2001-05-25
LU90617B1 (fr) 2001-06-15
MD2336G2 (ro) 2004-06-30
MD20000162A (en) 2001-04-30
LV12623A (en) 2001-03-20
SG91296A1 (en) 2002-09-17
AT502318A1 (de) 2007-02-15
HU0003001D0 (en) 2000-10-28
KR20010049916A (ko) 2001-06-15
PT102502A (pt) 2001-01-31
ITMI20001759A1 (it) 2002-01-28
TR200002206A2 (tr) 2001-03-21
MXPA00007461A (es) 2004-07-16
GR20000100265A (el) 2001-03-30
NL1015821A1 (nl) 2001-01-30
CO5180570A1 (es) 2002-07-30
SV2002000132A (es) 2002-06-07

Similar Documents

Publication Publication Date Title
DK200001150A (da) Ny krystallinsk form af 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen hydrochlorid
DK200001151A (da) Ny krystallinsk form af 6-hydorxy-3-(-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]tihiophen hydrochlorid
RU2120443C1 (ru) 2-фенилбензо(в)фураны и -тиофены и способ их получения
US5962475A (en) Substituted benzo(B)thiophene compounds having activity as selective estrogen receptor modulators
US5952350A (en) Naphthyl compounds and compositions, as estrogen receptor binding agents
EA003471B1 (ru) 2-АРИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ
US6403615B1 (en) 2-Aryl-3-aroylbenzo {b} thiophenes useful for the treatment of estrogen deprivation syndrome
US6075151A (en) Benzothiophene compounds, intermediates, processes, compositions, and methods
RU2000120574A (ru) НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗ[b]ТИОФЕНА ГИДРОХЛОРИДА
EP0832888B1 (en) Benzothiophene compounds, compositions, and methods
EP0905132A1 (en) Benzothiophenes
RU2000120575A (ru) НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗ[b]ТИОФЕНА ГИДРОХЛОРИДА
JP2001525318A (ja) ベンゾチオフェン類
EP0838461A2 (en) Substituted 2,3-aryl-benzothiophene compounds having estrogenic activity
WO2002034741A3 (en) A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE
US5821253A (en) Tetrahydrobenzo a!fluorene compounds and methods of use

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment